If Co-pay Factored, Novartis Beats Generic Glivec By A Tenth In India
This article was originally published in PharmAsia News
Executive Summary
Down but not out following the denial of a patent for Glivec in India, Novartis said co-pays allow it to offer the drug at rates that beat generics at their own game.